FOR IMMEDIATE RELEASE
February 18, 2002

Burlington, Ontario

THE JENEX CORPORATION ("Jenex" or the "Corporation") (CDNX - JEN), reports they have submitted their response to the questions received from the FDA, in reference to their Premarket Notification application. (Re: requesting clearance to market their medical device, for the prevention of cold sores) Jenex (www.jenexcorp.com) is seeking clearance from the FDA to make a similar claim in the United States, to the one received from Health Canada's Therapeutic Products Programme (TPP). The Corporation was issued a license to market their device as an OTC (over-the-counter) product in Canada with the claim: "For prevention and relief of the symptoms of herpes labialis (cold sores), such as blistering, lesions, inflammation, and discomfort. Also helps alleviate the embarrassment that is typically associated with herpes labialis (cold sore) outbreaks". The Corporation expects a reply from FDA in the 2nd quarter of 2002.

Jenex is the first company to receive marketing clearance from an internationally recognized regulatory body to make the prevention claim for cold sores. The HSV-1 virus that causes cold sores, is endemic in North America, and is estimated to affect 80% of the population. As the only product clinically proven to prevent the outbreak of cold sores, the Corporation's thermal therapy product has the potential to dominate a large and underdeveloped market.

"Prevention is the Solution"

Michael A. Jenkins, President
The Jenex Corporation
207 - 940 Sheldon Court
Burlington, Ontario
L7L 5K6
Telephone: (905) 632-3830
Facsimile: (905) 632-3774
Email: Jenex@sprint.ca
Web Site: www.jenexcorp.com

The Canadian Venture Exchange Inc. has not reviewed and does not a